medigraphic.com
ISSN 1527-3172 (Digital)

2022, Número 2

<< Anterior Siguiente >>

MEDICC Review 2022; 24 (2)


Hematological Alterations in Patients Recovered from SARS-CoV-2 Infection in Havana, Cuba

Pereira-Roche N, Roblejo-Balbuena H, Marín-Padrón LC, Sotomayor-Lugo F, González-Torres MÁ, Pérez-Rodríguez J, Álvarez-Gavilán Y, Torres-Rives B, Bravo-Ramírez M, Benítez-Codero Y, Monzón-Benítez G, Silva-Ayçaguer LC, Marcheco-Teruel B

Idioma: Ingles.
Referencias bibliográficas: 46
Paginas: 7-14
Archivo PDF: 243.98 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Tang D, Comish P, Kang R. The hallmarksof COVID-19 disease. PLoS Pathogen. 2020;16(5):e1008536. https:// doi.org/10.1371/journal.ppat.1008536

  2. World Health Organization [Internet]. Novel Coronavirus(2019-nCoV) Situation Report – 22; 2020Feb 11 [cited 2020 Feb 20]. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf

  3. Gandhi RT, Lynch JB, del Rio C. Mild to moderateCovid-19. N Engl J Med. 2020;383:1757‒66.https://doi.org/ 10.1056/NEJMcp2009249

  4. Xu J, Ma XP, Bai L, Wang M, Deng W, Ning N. Asystematic review of etiology, epidemiology, clinicalmanifestations, image fi ndings, and medicationof 2019 Corona Virus Disease-19 in Wuhan,China. Medicine [Internet]. 2020 [cited 2020 Dec18];99:42(e22688). Available at: http://dx.doi.org/10.1097/MD.0000000000022688

  5. Dhama K, Khan S, Tiwari R, Sircar S, Bhat S,Malik YS, et al. Coronavirus Disease 2019–COVID-19. Clin Microbiol Rev [Internet]. 2020[cited 2020 Oct 28];33(4):e00028-20. Availableat: https://journals.asm.org/doi/full/10.1128/CMR.00028-20

  6. Berlin DA, Gulik RM, Martínez FJ. Severe Covid-19. N Engl J Med. 2020 ;383:2451‒60. https://doi.org/10.1056/NEJMcp2009575

  7. Fan BE, Chong VCL, Chan SSW, Lim GH, LimKGE, Tan GB, et al. Hematologic parameters inpatients with COVID-19 infection. Am J Hematol.2020;95(6):E131-E134. https://doi.org/10.1002/ajh.25774

  8. Lippi G, Plebani M. Laboratory abnormalitiesin patients with COVID-2019 infection. ClinChem Lab Med. 2020;58(7):1131–4. https://doi.org/10.1515/cclm-2020-0198

  9. Yun H, Sun Z, Wu J, Tang A, Hu M, Xiang Z.Laboratory data analysis of novel coronavirus(COVID-19) screening in 2510 patients. Clin ChimicaActa. 2020;507:94–7. https://doi.org/10.1016/j.cca.2020.04.018

  10. Lu G, Wang J. Dynamic changes in routine bloodparameters of a severe COVID-19 case. ClinicaChimica Acta. 2020;508:98–102. https://doi.org/10.1016/j.cca.2020.04.034

  11. Chen J, Pan Y, Li G, Xu W, Zhang L, Yuan S, etal. Distinguishing between COVID–19 and infl uenzaduring the early stages by measurement ofperipheral blood parameters. J Med Virol [Internet].2020 [cited 2020 Dec 18];1–9. Available at:https://doi.org/10.1002/jmv.26384

  12. Liao D, Zhou F , Luo L, Xu M, Wang H, XiaJ, et al. Haematological characteristicsand risk factors in the classification andprognosis evaluation of COVID-19: a retrospectivecohort study. Lancet Haematology.2020;7(9):e671–e678. https://doi.org/10.1016/S2352-3026(20)30217-9

  13. Yan B, Yang J, Xie Y, Tang X. Relationship betweenblood eosinophil levels and COVID-19 mortality.World Allergy Organ J. [Internet]. 2021 [cited 2021May 12];14(3):100521. http://doi.org/10.1016/j.waojou.2021.100521

  14. Stone JR, Tran KM, Conklin J, Mino-KenudsonM. Case record of the Massachusetts GeneralHospital. Case 23-2020: a 76-year-old womanwho died from Covid-19. N Engl J Med [Internet].2020 [cited 2020 Oct 28];383:380−7. Available at:https://www.nejm.org/doi/full/10.1056/NEJMcpc2004974

  15. Terpos E, Ntanasis-Stathopoulos I, ElalamyI, Kastritis E, Sergentanis TN, Politou M, etal. Hematological fi ndings and complicationsof COVID-19. Am J Hematol [Internet]. 2020[cited 2020 Oct 28];95(7):834−47. https://doi.org/10.1002/ajh.25829

  16. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C,et al. Neutrophil to lymphocyte ratio predictscritical illness patients with 2019 coronavirusdisease in the early stage. J TranslMed. 2020;18:206. https://doi.org/10.1186/s12967-020-02374-0

  17. Lagunas-Rangel FA. Neutrophil–o–lymphocyteratio and lymphocyte-to-C-reactive protein ratioin patients with severe coronavirus disease2019 (COVID–19): A meta-analysis. J MedVirol. 2020;92:1733–4. https://doi.org/ 10.1002/jmv.25819

  18. Rodrigo-Muñoz JM, Sastre B, Cañas JA, Gil-Martínez M, Redondo N, del Pozo V. Eosinophilresponse against classical and emergingrespiratory viruses: COVID-19. J InvestigAllergol Clin Immunol. 2021;31(2). https://doi.org/10.18176/jiaci.0624

  19. Mateos González M, Sierra Gonzalo E, CasadoLopez I, Arnalich Fernández F, Beato Pérez JL,Monge Monge D, et al. The Prognostic Valueof Eosinophil Recovery in COVID-19: Multicentre,retrospective cohort study on patientshospitalised in Spanish hospitals. J. Clin.Med. 2021;10(2):305. https://doi.org/10.3390/jcm10020305

  20. Xie G, Ding F, Han L, Yin D, Lu H, Zhang M.The role of peripheral blood eosinophil countsin COVID-19 Patients. Allergy. 2020;10:1–12.https://doi.org/10.1111/all.14465

  21. Fraisse M, Logre E, Mentec H, Cally R, PlantefeveG, Contou D. Eosinophilia in critically illCOVID-19 patients: a French monocenter retrospectivestudy. Crit Care. 2020;24:635. https://doi.org/10.1186/s13054-020-03361-z

  22. Ministry of Public Health (CU). Protocolo de actuaciónnacional para la COVID-19. Versión 1.5 [Internet].Havana: Ministry of Public Health (CU); 2020 Aug.[cited 2020 Aug 31]. Available at: https://covid19cubadata.github.io/protocolos/protocolo-version-5.pdf. Spanish

  23. COVID-19 Cuba Data [Internet]. Havana: Cuba-Data; c2020 [updated 2021 Sep 10; cited 2020Jun 15] [revised 2020 Jun 15]. Available at:https://covid19cubadata.github.io/#cuba. Spanish

  24. Escobar Carmona E. Valores de referencia delLaboratorio Clínico más empleados en Cuba.Año 2011. Gaceta Médica Espirituana [Internet][cited 2020 Aug 31]; 2011;13(2). Available at:http://revgmespirituana.sld.cu/index.php/gme/article/view/257. Spanish

  25. Mindray Bio-Medical Electronics Co [Internet].Madrid: Mindray; c2020. Productos. Diagnósticoin vitro. Analizadores hematológicos y reactivos.5-Diff Hematología. BC-6800 analizadorautomático para hematología; [cited 2020 Oct 26]; [about 3 p.]. Available at: https://www.mindray.com/es/product/BC-6800.html. Spanish.

  26. Center for State Control of Medicines, Equipmentand Medical Devices (CU). Havana:Center for State Control of Medicines, Equipmentand Medical Devices (CU).; c2022. Cuba.Regulación no.3-2009. Buenas Prácticas deLaboratorio Clínico; 2009 [cited 2015 Oct 14].Available at: HYPERLINK "http://www.cecmed.cu/sites/default/fi les/adjuntos/Reglamentacion/Reg_03-09.pdf"http://www.cecmed.cu/sites/default/files/adjuntos/Reglamentacion/Reg_03-09.pdf#overlay-context=reglamentacion/aprobadas%3Fpage%3D8. Spanish.

  27. Liu L, Shan H, Lei C, Hui DSC, Du B, Li L, etal. Clinical characteristics of coronavirus disease2019 in China. N Engl J Med [Internet].2020 [cited 2020 Oct 28];382:1708−20. Availableat: https://www.nejm.org/doi/full/10.1056/neJMoa2002032

  28. Dubey AK, Singh A, Prakash S, Kumar M, SinghAK. Race to arsenal COVID-19 therapeutics:Current alarming status and future directions.Chem Biol Interact. 2020;332:109298. https://doi.org/10.1016/j.cbi.2020.109298

  29. World Health Organization [Internet]. Geneva:World Health Organization; c2022. Publications.Overview. Living guidance for clinical managementof COVID-19; 2021 Nov 23 [cited 2021 Dec 10].Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2

  30. Poland GA, Ovsyannikova IG, Kennedy RB.SARS-CoV-2 immunity: review and applicationsto phase 3 vaccine candidates. Lancet.2020;4:396(10262):1595−606. https://doi.org/10.1016/S0140-6736(20)32137-1

  31. Rodriguez L, Pekkarinen PT, Lakshmikanth T,Tan Z, Consiglio CR, Pou C, et al. Systems-level immunomonitoring from acute to recoveryphase of severe COVID-19. Cell Rep Med.2020;1(5):100078. https://doi.org/10.1016/j.xcrm.2020.100078.

  32. Wang C, Deng R, Gou L, Fu Z, Zhang X, ShaoF, et al. Preliminary study to identify severefrom moderate cases of COVID-19 using combinedhematology parameters. Ann Transl Med.2020 [cited 2020 Oct 28];8(9):593. https://doi.org/10.21037/atm-20-3391

  33. Zhao G, Su Y, Sun X, Cui X, Dang L, Zhao L,et al. A comparative study of the laboratoryfeatures of COVID-19 and other viral pneumoniasin the recovery stage. J Clin Lab Anal.2020;34(10):e23483. https://doi.org/10.1002/jcla.23483

  34. Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andréll J, et al. Persistence ofSARS-CoV-2-specifi c B and T cell responsesin convalescent COVID-19 patients 6-8 monthsafter the infection. Med (NY). 2021;2(3):281−95.https://doi.org/10.1016/j.medj.2021.02.001

  35. Liang J, Nong S, Jiang L, Chi X, Bi D, Cao J,et al. Correlations of disease severity and agewith hematology parameter variations in patientswith COVID-19 pre- and post-treatment. JClin Lab Anal. 2021;35(1):e23609. https://doi.org/10.1002/jcla.23609

  36. Shaw B, Daskareh M, Gholamrezanezhad A. Thelingering manifestations of COVID-19 during andafter convalescence: update on long-term pulmonaryconsequences of coronavirus disease 2019(COVID-19). Radiol Med. 2021;126(1):40−6.https://doi.org/10.1007/s11547-020-01295-8

  37. Sonnweber T, Sahanic S, Pizzini A, Luger A,Schwabl C, Sonnweber B, et al. Cardiopulmonaryrecovery after COVID-19: an observationalprospective multicentre trial. EurRespir J. 2021;57(4):2003481. https://doi.org/10.1183/13993003.03481-2020

  38. Frenkel A, Kachko E, Cohen K, Novack V,Maimon N. Estimations of a degree of steroidinduced leukocytosis in patients with acute infections.Am J Emerg Med. 2018 ;36(5):749−53.https://doi.org/10.1016/j.ajem.2017.10.003

  39. Shoenfeld Y, Gurewich Y, Gallant LA, PinkhasJ. Prednisone-induced leukocytosis. Infl uenceof dosage, method and duration of administrationon the degree of leukocytosis. Am J Med.1981;71(5):773−8. https://doi.org/10.1016/0002-9343(81)90363-6

  40. Taneri PE, Gómez-Ochoa SA, Llanaj E,Raguindin PF, Rojas LZ, Roa-Díaz ZM, et al.Anemia and iron metabolism in COVID-19: a systematicreview and meta-analysis. Eur J Epidemiol.2020;35(8):763−73. https://doi.org/10.1007/s10654-020-00678-5

  41. Cavezzi A, Troiani E, Corrao S. COVID-19: hemoglobin,iron, and hypoxia beyond infl ammation. Anarrative review. Clin Pract. 2020;10(2):1271.https://doi:10.4081/cp.2020.1271

  42. Tao Z, Xu J, Chen W, Yang Z, Xu X, Liu L, et al. Anemiais associated with severe illness in COVID-19:A retrospective cohort study. J Med Virol.2021;93(3):1478−88. https://doi.org/10.1002/jmv.26444

  43. Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, et al.Patients of COVID-19 may benefi t from sustainedLopinavir-combined regimen and the increase ofEosinophil may predict the outcome of COVID-19progression. Int J Infect Dis. 2020;95:183−91.https://doi.org/10.1016/j.ijid.2020.03.013

  44. Hartl S, Breyer MK, Burghuber OC, OfenheimerA, Schrott A, Urban MH, et al. Bloodeosinophil count in the general population:typical values and potential confounders. EurRespir J. 2020;55(5):1901874. https://doi.org/10.1183/13993003.01874-2019

  45. Caspard H, Ambrose CS, Tran TN, Chipps BE,Zeiger RS. Associations between individualcharacteristics and blood eosinophil countsin adults with asthma or COPD. J Allergy ClinImmunol Pract. 2020;8(5):1606‒13. https://doi.org/10.1016/j.jaip.2019.12.019

  46. Kumar A, Cherian SV, Vassallo R, Yi ES, Ryu JH.Current concepts in pathogenesis, diagnosis,and management of smoking-related Interstitiallung diseases. Chest. 2018;154(2):394‒408.https://doi.org/10.1016/j.chest.2017.11.023.




2020     |     www.medigraphic.com